© РИА Томск. Яков Андреев
TOMSK, Feb
25 – RIA Tomsk. Scientists of Tomsk State University (TSU) together with
colleagues from other Siberian research centers developed a new drug for
influenza treatment and prevention; preclinical studies have shown that
antiviral activity of the drug is almost two times higher than the well-known
foreign counterpart, the university’s press service said on Tuesday.
It is
specified that the project was implemented within the framework of the federal
target program "Pharma 2020". It is attended by employees of TSU,
Institute for Problems of Chemical and Energetic Technologies of the Siberian
Branch of the RAS (IPCET SB RAS, Biysk), and Goldberg Research Institute of
Pharmacology and Regenerative Medicine Clinic of Tomsk National Research
Medical Center (Tomsk NRMC). The industrial partner of the project is
scientific and production centre Chemical Technologies (SPC ChT).
"Most pharmaceutical
substances are manufactured in China. It is important for Russia to change this
proportion by creating domestic drugs that are not inferior to foreign ones in
efficiency. One of these drugs appeared as a result of the joint work of TSU,
two academic institutes and SPC ChT", – the vice-rector of TSU for
scientific and innovative activities Alexander Vorozhtsov is quoted.
© РИА Томск. Павел Стефанский
It is
specified that scientists have developed a new technology for the synthesis of
the pharmaceutical substance of oseltamivir ethoxy succinas and received a drug
with a double antiviral effect. According to the developers, the innovative
oseltamivir may appear on the market by 2025.
"There
is already a finished dosage form. A patent has been received for the drug. The
results of preclinical studies showed that the new drug has improved
characteristics. Its antiviral activity was almost two times higher than that
of the famous Swiss drug Tamiflu, which is widely used for influenza treatment",
– is said in the report.
According
to the university, studies conducted by Siberian pharmacologists have shown
that the new drug is characterized by low general and chronic toxicity, does
not have a mutagenic, carcinogenic and allergenic effect. It is expected that
the production of the drug and its final cost to the consumer will be
significantly lower than the cost of the foreign counterpart.